At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Brimonidine Tartratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Enhanced Pupil Dilation in Patients Taking Alpha-Blockers for Potential Treatment of Intraoperative Floppy Iris Syndrome
In Brief
A Phase 2 clinical trial evaluating Brimonidine Tartrate for Intraoperative Floppy Iris Syndrome. Completed, enrolled 13 participants across 1 site.
Detailed Summary
A novel intervention for targeting the treatment of Intraoperative Floppy Iris Syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraoperative Floppy Iris Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionSep 2020
TodayJul 2026
First PostedNov 30, 2018
Enrollment StartJan 4, 2019
Primary CompletionSep 25, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.6 years ago
Interventions
Brimonidine Tartratedrug
All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.